Comparative Pharmacology
Head-to-head clinical analysis: EVOCLIN versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOCLIN versus POLYSPORIN.
EVOCLIN vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic